The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope
about
Pathogenesis of human immunodeficiency virus infectionA synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibitionDeterminants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence.Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationHow can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.Neutralizing antibodies to HIV-1 induced by immunization.Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralizationResistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralizationCross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoproteinNeutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.
P2860
Q24634681-FF3580B9-AC0E-4551-8AEB-77D97743C1C0Q28317348-61461415-F688-4158-85C6-B09DAEC94167Q28379310-39D541B2-5391-45FE-B639-C785753D662EQ33313394-BC660D93-9F1A-4B4B-BB22-4BE380AA81D4Q33719511-40244382-2A36-4F01-B110-EAED6D091125Q33783763-8B3C4110-8825-4CED-AE0A-BEFE2864271CQ33786382-DD5B865D-FAAB-40FE-AE05-E95C8E34F047Q33803590-CC64E7B9-4814-4419-A113-A9841C18BB72Q33839485-13200B08-D855-45CA-8316-6482B3F52A7DQ33936492-E16CF098-B912-4F45-8769-E73562BEB5E1Q35105006-DC8002BB-418B-4776-A6A5-C079F822B73EQ35274763-88D0A5E9-50E9-407D-B7C3-4FFCBBC2FE39Q35644971-F910F372-9EFA-4FB4-970B-D301B4920D96Q35653703-D7AD0466-1847-4CF0-883B-0C014B461108Q35833979-A9CD58EE-FC69-43C6-B6EA-22EA2E4830BAQ35835261-E5EBF3E1-E3FD-4D7F-8C0E-993263F2BD5DQ35873306-6741E939-AA0B-478B-B82F-197B2635543FQ36246315-3AD0E6ED-BE98-47FE-B6A3-A5FE7425E094Q36603515-0B05287C-DC61-4651-AD73-97E3572CFCBAQ36626451-58B132AF-9B15-4933-8BAE-F85C8F82FBC3Q36626986-83C11567-6CE9-484E-9094-96E66CE4EBD3Q36633911-FD4126C6-C993-41E0-B628-28766B14736AQ36651761-9FCF72BE-2954-4079-9BA8-B6D1D4BF4BDEQ36654750-DD58E0B1-31E5-4051-8B6E-4D31B6665737Q36655438-50F544DB-0615-4AD5-8D6B-5C67A5636C93Q36683893-D1ED0C2C-4E12-4F83-B911-6C5C32E51C4AQ36686562-B199EFD3-CF2B-4018-B4EF-37C0A2EEEAAEQ36698091-93C66C52-4DAD-4D78-B125-EB45DD2682CEQ36898925-C16E2321-FFED-41BD-9EDE-49481330C0A8Q37596501-5B0DE611-F51B-4BA5-9963-D095E388D5D7Q39594428-FF439553-DEB0-4F78-90EE-8BF9C1E7B827Q39684388-50EC8DD4-5E51-4049-ADC1-7B8BDE3EF89FQ39871315-98B8C711-B175-461A-9D03-631371C1B7CEQ40295939-7593FC8F-B0F0-49DC-BCB4-C9E3B8248FA5Q40399853-8477D463-21DC-45AD-9788-85DC342ED9A1
P2860
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
The site of an immune-selected ...... ute the neutralization epitope
@ast
The site of an immune-selected ...... ute the neutralization epitope
@en
type
label
The site of an immune-selected ...... ute the neutralization epitope
@ast
The site of an immune-selected ...... ute the neutralization epitope
@en
prefLabel
The site of an immune-selected ...... ute the neutralization epitope
@ast
The site of an immune-selected ...... ute the neutralization epitope
@en
P2093
P2860
P1433
P1476
The site of an immune-selected ...... ute the neutralization epitope
@en
P2093
Reitz MS Jr
Robert-Guroff M
P2860
P304
P407
P577
1990-07-01T00:00:00Z